On the second day the main conference programme commences with presentations on dosing techniques for powders, liquids, gases, vapours, fragile molecules, also addressing clinical device design/incorporation into preclinical studies. This is followed by presentations on design and operational considerations relating to intranasal, whole-body, head only, large animal and juvenile exposure systems.

The final day will include presentations on aerosol monitoring methodology (collection, sizing, real-time), respiratory rate measurement methodology (plethysmography, telemetry), dose calculation with reference to pharmaceutical and chemical studies, through industry experience of regulatory attitudes to newer approaches (oligonucleotides) and ending with an animated (hopefully) open forum discussion of client/regulatory interactions when presented with developing drug therapies